Related Experiment Video

Updated: May 13, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a

Panpan Zhang1, Zuoxing Niu2, Hongqian Guo3

  • 1Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Early Drug Development Centre, Peking University Cancer Hospital & Institute, Beijing, 100142, China.

Nature Communications
|May 11, 2026
PubMed

Insights

Tinengotinib, a multi-kinase inhibitor, showed good safety and antitumor activity in advanced solid tumors. It demonstrated promise in cholangiocarcinoma, especially when combined with atezolizumab.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Tinengotinib is a novel multi-kinase inhibitor targeting FGFR, JAK, VEGFR, and Aurora kinases.
  • Advanced solid tumors, particularly biliary tract cancer, present significant treatment challenges.

Purpose of the Study:

  • To evaluate the safety, tolerability, and efficacy of tinengotinib as monotherapy and in combination with atezolizumab.
  • To determine the maximum tolerated dose (MTD) and select doses for phase II expansion.

Main Methods:

  • A phase Ib/II clinical trial (NCT05253053) with dose-escalation and expansion phases.
  • Tinengotinib was administered as monotherapy (Arm A) or combined with atezolizumab (Arm B) in patients with advanced solid tumors and biliary tract cancer.

Main Results:

  • Tinengotinib was well-tolerated, with no dose-limiting toxicities (DLTs) or MTD reached.
  • Objective response rates (ORR) were 16.7% for tinengotinib monotherapy and 22.6% for the combination regimen.
  • Notable efficacy was observed in cholangiocarcinoma, with ORRs of 30.8% (monotherapy) and 25.0% (combination).

Conclusions:

  • Tinengotinib is safe and demonstrates antitumor activity in advanced solid tumors.
  • The combination of tinengotinib and atezolizumab shows potential for treating biliary tract cancer, supporting further clinical development.

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...